|
|
Volumn 4, Issue 5, 1992, Pages 338-340
|
|
FDA's policy statement for the development of new stereoisomeric drugs.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
ANIMAL;
ARTICLE;
BIOTRANSFORMATION;
CHEMISTRY;
DRUG DESIGN;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
METABOLISM;
STEREOISOMERISM;
UNITED STATES;
ADRENERGIC BETA-ANTAGONISTS;
ANIMALS;
BIOTRANSFORMATION;
DRUG DESIGN;
HUMANS;
STEREOISOMERISM;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0026437190
PISSN: 08990042
EISSN: None
Source Type: Journal
DOI: 10.1002/chir.530040513 Document Type: Article |
|
Times cited : (524)
|
|
References (0)
|